DSM Sinochem Pharmaceuticals sold to Bain Capital

Bain Capital has completed the acquisition of DSM Sinochem Pharmaceuticals (DSP) from DSM and Sinochem Group, who each held an equity stake of 50%. 

DSM received about €250 million for its equity stake, excluding an earn-out (estimated at around €50m) and transaction costs. DSM anticipates a book profit of about €110 million on the transaction to be recognized in Q4 2018.

DSM expects to receive approximately €275 million in cash following closing, including repayment of debt and after transaction costs.